7 active not recruiting. 7 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Active not recruiting 7 |
Follow Primary Myelofibrosis: new trials by email Literature Review of Primary Myelofibrosis trials Research Report on Primary Myelofibrosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| P1101 in Treating Patients With Early PMF or Overt PMF at Low or Intermediate-1 Risk Ropeginterferon alfa-2b, Placebo - Primary Myelofibrosis, Myeloproliferative Neoplasm | Phase 3 | Active not recruiting | PharmaEssentia | 160 | 2025-07-18 | 2026-08-13 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2) Pelabresib, Ruxolitinib, Placebo - Myelofibrosis, Primary Myelofibrosis | Phase 3 | Active not recruiting | Novartis Pharmaceuticals | 430 | 2021-04-09 | 2026-07-17 |
| Study of Selinexor in Combination With Ruxolitinib in Myelofibrosis Selinexor, Placebo, Ruxolitinib - Myelofibrosis | Phase 3 | Active not recruiting | Karyopharm Therapeutics Inc | 353 | 2021-03-11 | 2026-11-04 |
| An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions ACE-536, Placebo - Myeloproliferative Disorders, Myelofibrosis | Phase 3 | Active not recruiting | Celgene | 313 | 2021-02-25 | 2026-07-16 |
| Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis Navitoclax, Ruxolitinib, Best Available Therapy (BAT) - Myelofibrosis (MF) | Phase 3 | Active not recruiting | AbbVie | 330 | 2020-08-31 | 2026-01-09 |
| A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis Pacritinib, Physician's Choice medications - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Active not recruiting | Swedish Orphan Biovitrum | 407 | 2017-06-26 | 2026-04-30 |
Myeloproliferative Disorders (4) · Anemia (2) · Blood Platelet Disorders (1) · Bone Marrow Diseases (1) · Hematologic Diseases (1) · Hemorrhagic Disorders (1) · Neoplasms (1) · Polycythemia (1) · Splenomegaly (1) · Thrombocytosis (1)
Hemic and Lymphatic Diseases (7) · Bone Marrow Diseases (6) · Hematologic Diseases (6) · Myeloproliferative Disorders (3) · Blood Platelet Disorders (1) · Hypertrophy (1) · Pathological Conditions, Anatomical (1) · Pathological Conditions, Signs and Symptoms (1)
ruxolitinib (4) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (1) · Adrenal Cortex Hormones (1) · Danazol (1) · GRN163L peptide (1) · Hydroxyurea (1) · imetelstat (1) · luspatercept (1) · navitoclax (1) · selinexor (1)
AbbVie (1) · Celgene (1) · Geron Corporation (1) · Karyopharm Therapeutics Inc (1) · Novartis Pharmaceuticals (1) · PharmaEssentia (1) · Swedish Orphan Biovitrum (1)
South Korea (7) · United States (7) · Australia (6) · Canada (6) · France (6) · Hungary (6) · Israel (6) · Italy (6) · Poland (6) · Spain (6) · United Kingdom (6) · Belgium (5) · Czechia (5) · Germany (5) · Taiwan (5)
Joe Eid (1) · Simran Singh (1) · Toshiaki Sato, MD/PhD (1)
PMID 33232476, PMID 35510486, PMID 35950489, PMID 39911057, PMID 40065169, PMID 41785311, PMID 42227656, PMID 42842696
2023 (4)